Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase 1 Study of JADE201 in Participants With Rheumatoid Arthritis
Sponsor: Jade Biosciences, Inc.
Summary
This is a Phase 1, first in human study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of JADE201 compared to placebo in participants with Rheumatoid Arthritis
Official title: A Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JADE201 Administered Subcutaneously in Participants With Rheumatoid Arthritis
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
36
Start Date
2026-05-19
Completion Date
2028-10
Last Updated
2026-10-23
Healthy Volunteers
No
Conditions
Interventions
JADE201
JADE201 is supplied as sterile solution to be administered by SC injection.
Placebo
Placebo solution to be administered at a matching volume by SC injection.
Locations (8)
Jade Clinical Site
Sofia, Bulgaria
Jade Clinical Site
Tbilisi, Georgia
Jade Clinical Site
Berlin, Germany
Jade Clinical Site
Chisinau, Moldova, Moldova
Jade Clinical Site
Bucharest, Romania
Jade Clinical Site
Cluj-Napoca, Romania
Jade Clinical Site
Ivano-Frankivsk, Ukraine, Ukraine
Jade Clinical Site
Kyiv, Ukraine, Ukraine